Galmed Pharma (GLMD) Misses Q1 EPS by 3c

Galmed Pharma (NASDAQ: GLMD) reported Q1 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Galmed completes Colospan acquisition under restructured terms
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits